1. Home
  2. ITGR vs ABCL Comparison

ITGR vs ABCL Comparison

Compare ITGR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integer Holdings Corporation

ITGR

Integer Holdings Corporation

SELL

Current Price

$126.70

Market Cap

4.3B

Sector

Health Care

ML Signal

SELL

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

SELL

Current Price

$11.84

Market Cap

4.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ITGR
ABCL
Founded
1970
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
4.1B
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
ITGR
ABCL
Price
$126.70
$11.84
Analyst Decision
Hold
Strong Buy
Analyst Count
9
12
Target Price
★ $121.80
$16.82
AVG Volume (30 Days)
678.5K
★ 5.0M
Earning Date
10-30-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 10.91
EPS
★ 1.17
N/A
Revenue
★ $1,853,637,000.00
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.96
$7.12
P/E Ratio
$108.32
★ N/A
Revenue Growth
7.98
★ 160.56
52 Week Low
$62.00
$2.75
52 Week High
$126.80
$14.98

Technical Indicators

Market Signals
Indicator
ITGR
ABCL
Relative Strength Index (RSI) 72.72 44.43
Support Level $126.16 $11.78
Resistance Level $126.80 $12.88
Average True Range (ATR) 0.13 0.78
MACD -0.21 -0.26
Stochastic Oscillator 79.41 4.36

Price Performance

Historical Comparison
ITGR
ABCL

About ITGR Integer Holdings Corporation

Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: